What are your top takeaways in Hematologic Malignancies from ASCO 2026?

1. Phase III SENTRY study of ruxolitinib +/- selinexor in myelofibrosis - The combination arm met the spleen response endpoint, had similar rates of symptom improvement compared to ruxolitinib, and, with short follow-up, there appears to be a signal towards survival benefit. Longer-term follow-up will help to better define the impact of this study.
2. Impact of Obi-cel in patients with R/R B-ALL that have extramedullary disease - R/R B-ALL with extramedullary disease has historically been a very hard...

1. MajesTEC-9 study: Started teclistamab in a real-world post-lenalidomide and CD38 population.
2. SUCCESSOR-2 study: 1st randomized data on a celmod, which represents a now active oral drug class.
3. Kelonia CAR-T: Exciting early data on an in vivo CAR T, which could represent a paradigm shift in the future if long-term efficacy and safety data are as positive.

1. It is not really hematology, but it was so compelling that I will list it- the presentation reporting that the RAS-targeting drug daraxonrasib doubled overall survival in pancreatic cancer. Clearly important for RAS-driven tumors, but the chemistry behind it will benefit efforts to target previously undruggable proteins.

#2 and #3 weren't single presentations but clusters of talks about promising new developments:

2. Uses and impact of menin inhibitors on leukemia therapy.

3. Increasing posit...

1. MajesTEC-9 trial. In my opinion, this is a very relevant study in today’s treatment era (where everybody receives upfront anti-CD38 mAb therapy). There was substantial PFS benefit, and the study included rapid de-escalation of teclistamab dosing frequency. I think single-agent teclistamab will be an important salvage option for patients in early lines of relapse who are not CAR T eligible or who do not want to pursue CAR T.
2. SUCCESSOR-2 trial. MeziKd will be another effective salvage option, with ...

As always, lots of compelling data were presented at ASCO highlighting the advancements we continue to see in the treatment of plasma cell disorders. My top takeaways include:

1. Phase 3 randomized trial to evaluate the impact of anselamimab on all-cause mortality in κ light-chain amyloidosis: for decades, we have been desperately trying to develop effective anti-fibril therapy to remove deposited amyloid fibrils that cause end-organ damage in AL amyloidosis. The CARES studies (NCT04512235 and NC...

frontMIND – Study evaluating the benefit of R2-tafa+ CHOP compared to R-CHOP in patients with newly diagnosed DLBCL. The study demonstrated a PFS benefit of the experimental arm (R2-tafa-CHOP) vs. R-CHOP. There was no OS benefit. The study indicated increased toxicity with the experimental arm, but this did not induce any unexpected/unexplained deaths. The PFS benefit is similar to what was seen in the POLARIX study. Given the ease of use, would likely still favor Pola-R-CHP in non-GCB patients,...

• I think some of the most impressive were the data on elranatamab in smoldering MM and the ERASMM study from Europe.
• Linvoseltamab data in AL amyloidosis in the relapsed setting.
• And the KLN-1010 in vivo CART data for relapsed myeloma.